Dr. Tong joined Surface Logix in August 2004. He brings over 12 years of pharmaceutical experience to Surface Logix. Prior to joining Surface Logix, Dr. Tong was a Vice President in World Wide Development at GlaxoSmithKline (GSK). Also at GSK, Dr. Tong held the positions of Vice President, Global Commercial Strategy for Anti-Infectives, Regional Business Development Director for Asia Pacific and Medical Director in New Zealand. In his commercial role at GSK, Dr. Tong was responsible for a franchise with annual global sales in excess of $3.2 billion and was responsible for launching two new anti-viral products. He has also led business development activities on a regional basis and in-licensing negotiations for a number of global assets at different stages of development. Dr. Tong is qualified as Senior Scholar in Medicine from Auckland University.

Mr. Henderson joined Surface Logix in May 2000. Prior to joining Surface Logix, Mr. Henderson was an attorney with Kenyon & Kenyon. Prior to Kenyon & Kenyon, Mr. Henderson worked as a consultant for Accenture (formerly, Andersen Consulting). His experience covers many areas of intellectual property, including patent, trademark and copyright litigation, licensing and prosecution, corporate intellectual property strategy, valuation and due diligence. Mr. Henderson's patent litigation and prosecution experience is focused primarily in life sciences including biotechnology and medical-related devices. Mr. Henderson received both his B.S. in Biomedical & Electrical Engineering from Duke University and his J.D. from Duke University School of Law.

Dr. Ferkany joined Surface Logix in July 2005 as Vice President of Biology bringing over 20 years of experience from the biotechnology, biopharmaceutical and contract research management industries. Prior to joining Surface Logix, Dr. Ferkany served as Senior Vice President for Virtual Drug Development Incorporated, a privately held biotechnology company engaged in developing therapeutic strategies for biodefense. Dr. Ferkany has also served as Vice President and Chief Technical Officer of NovaScreen BioSciences Corporation, an international contract research organization providing screening, profiling and assay development services for pharmaceutical and biotechnology companies worldwide, and for government agencies including the National Institutes of Health. He also headed his own consulting firm focused on regulatory preclinical drug development. He also led the Central Nervous Research group at Nova Pharmaceutical Corporation, the first successful biotechnology spin-out from the Johns Hopkins University. Dr. Ferkany has a B.S. in Zoology from the University of Michigan, a doctoral degree in Biomedical Sciences from the University of Texas at Houston, and a Masters of Administrative Sciences awarded from the Johns Hopkins University in Baltimore.

Dr. Schueller joined Surface Logix in 1999 as one of its founding members. Dr. Schueller oversees scale-up and manufacture of active pharmaceutical ingredients and clinical trial materials and coordinates these activities with preclinical and clinical studies. Dr. Schueller received a Licence de Chimie from Université Pierre et Marie Curie (Paris VI), a Diplôme d’Ingénieur from Ecole Supérieure de Chimie Organique et Minérale (formerly located in Paris) and a Ph.D. in organic chemistry from Ohio State University. He was a postdoctoral fellow in the group of Prof. George Whitesides in the Department of Chemistry and Chemical Biology at Harvard University.

Dr. McCarthy joined Surface Logix in May 2006 as Vice President of Chemistry bringing over 10 years of pharmaceutical experience to the Company. Prior to joining Surface Logix, Dr. McCarthy held the position of Associate Director of Medicinal Chemistry at the Pfizer Research Technology Center in Cambridge, Ma. In this role Dr. McCarthy was responsible for managing medicinal and analytical chemistry in support of various drug discovery programs including targets in the areas of obesity, diabetes and inflammation. Prior to joining the Pfizer Cambridge site in 2001, Dr. McCarthy held the position of Project Leader in the Veterinary Medicine Research and Discovery Division in Groton, CT where she actively pursued the development of anti-obesity agents and was a key contributor to the discovery of Dirlotapide. Dr. McCarthy has a Ph.D. in organic chemistry from Brandeis University and conducted post-doctoral work in asymmetric catalysis at Boston College.
 

Dr. Kim joined Surface Logix in 1999 as one its founding members. Dr. Kim is responsible for the development and application of the Pharmacomer Technology Platform. In his most recent role as Director of Platform Application, he discovered SLx-4090, a gut-selective MTP inhibitor, currently in Phase 2 development. Dr. Kim received a B.A. from Hamilton College and a Ph.D. in physical organic chemistry from the Department of Chemistry at Harvard University under the guidance of Professor George Whitesides.